Reglan, a drug marketed to treat gastrointestinal problems, has been linked to a serious condition known as tardive dyskinesia (and a similar condition known as tardive dystonia).
A public health warning about the link between Reglan (metoclopramide) and tardive dyskinesia was recently issued by the FDA. Common symptoms of tardive dyskinesia include repetitive involuntary movement of the extremities, rapid eye movements/blinking, tongue protrusion, lip smacking, pursing and puckering, grimacing, and impaired movement of the fingers. There is no known treatment for this condition once it sets in.
Commentary by Shawn Cantley (click here for bio and contact info: Cantley Profile), a Kentucky product liability attorney: “Recently, many defective drug lawsuits have been consolidated into a class action lawsuit or something similar called a MDL (multi-district litigation). In 2009, the Judicial Panel on Multi-District Litigation, at the urging of the drug’s manufacturer, declined to consolidate the Reglan cases into a MDL. This potentially makes it more difficult for those people permanently injured by this drug. We represent Reglan victims on a contingency fee basis, meaning the client does not have to pay any fees or expenses unless there is a recovery.”
The FDA is required Regland’s manufacturer to place what’s known as a “black box” warning on the packaging detailing the aforementioned risks associated with the drug.